Cloned (Comment) | Organism |
---|---|
sequence comparisons | Homo sapiens |
sequence comparisons | Leishmania donovani |
sequence comparisons | Plasmodium falciparum |
sequence comparisons | Trypanosoma brucei |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(2S)-N-(2-cyclohexylethyl)-2-[[N-([3-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetyl)-L-seryl]amino]heptanamide | - |
Leishmania donovani | |
(2S)-N-(2-cyclohexylethyl)-2-[[N-([3-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetyl)-L-seryl]amino]heptanamide | - |
Plasmodium falciparum | |
(2S)-N-(2-cyclohexylethyl)-2-[[N-([3-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetyl)-L-seryl]amino]heptanamide | - |
Trypanosoma brucei | |
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one | - |
Homo sapiens | |
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one | - |
Leishmania donovani | |
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one | - |
Plasmodium falciparum | |
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one | - |
Trypanosoma brucei | |
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one | - |
Homo sapiens | |
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one | - |
Leishmania donovani | |
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one | - |
Plasmodium falciparum | |
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one | - |
Trypanosoma brucei | |
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide | - |
Homo sapiens | |
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide | - |
Leishmania donovani | |
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide | - |
Plasmodium falciparum | |
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide | - |
Trypanosoma brucei | |
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide | - |
Homo sapiens | |
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide | - |
Leishmania donovani | |
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide | - |
Plasmodium falciparum | |
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide | - |
Trypanosoma brucei | |
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide | - |
Leishmania donovani | |
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide | - |
Trypanosoma brucei | |
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide | - |
Homo sapiens | |
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide | - |
Leishmania donovani | |
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide | - |
Plasmodium falciparum | |
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide | - |
Trypanosoma brucei | |
2-([[trans-4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide | - |
Leishmania donovani | |
2-([[trans-4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide | - |
Plasmodium falciparum | |
2-([[trans-4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide | - |
Trypanosoma brucei | |
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile | - |
Homo sapiens | |
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile | - |
Leishmania donovani | |
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile | - |
Plasmodium falciparum | |
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile | - |
Trypanosoma brucei | |
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole | - |
Homo sapiens | |
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole | - |
Leishmania donovani | |
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole | - |
Plasmodium falciparum | |
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole | - |
Trypanosoma brucei | |
additional information | development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview; development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview | Homo sapiens | |
additional information | development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview | Leishmania donovani | |
additional information | development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview | Plasmodium falciparum | |
additional information | development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview | Trypanosoma brucei | |
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine | - |
Homo sapiens | |
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine | - |
Leishmania donovani | |
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine | - |
Plasmodium falciparum | |
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine | - |
Trypanosoma brucei | |
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide | - |
Homo sapiens | |
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide | - |
Leishmania donovani | |
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide | - |
Plasmodium falciparum | |
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide | - |
Trypanosoma brucei | |
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine | - |
Homo sapiens | |
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine | - |
Leishmania donovani | |
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine | - |
Plasmodium falciparum | |
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine | - |
Trypanosoma brucei | |
[4-[3-(benzylamino)propoxy]-3-methyl-1-benzofuran-2-yl](1-methyl-1H-imidazol-2-yl)methanone | - |
Leishmania donovani | |
[4-[3-(benzylamino)propoxy]-3-methyl-1-benzofuran-2-yl](1-methyl-1H-imidazol-2-yl)methanone | - |
Plasmodium falciparum | |
[4-[3-(benzylamino)propoxy]-3-methyl-1-benzofuran-2-yl](1-methyl-1H-imidazol-2-yl)methanone | - |
Trypanosoma brucei |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | O60551 | NMT isoform HsNMT2; NMT isoform HsNMT2 | - |
Homo sapiens | P30419 | NMT isoform HsNMT1; NMT isoform HsNMT1 | - |
Leishmania donovani | D0AB09 | - |
- |
Plasmodium falciparum | Q8ILW6 | - |
- |
Trypanosoma brucei | D0A003 | - |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA | Homo sapiens | ? | - |
? | |
additional information | N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA | Leishmania donovani | ? | - |
? | |
additional information | N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA | Trypanosoma brucei | ? | - |
? | |
myristoyl-CoA + peptide CAP5.5 | N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein | Plasmodium falciparum | CoA + N-myristoyl-peptide CAP5.5 | - |
? |
Synonyms | Comment | Organism |
---|---|---|
HsNMT1 | - |
Homo sapiens |
HsNMT2 | - |
Homo sapiens |
N-myristoyltransferase | - |
Homo sapiens |
N-myristoyltransferase | - |
Leishmania donovani |
N-myristoyltransferase | - |
Plasmodium falciparum |
N-myristoyltransferase | - |
Trypanosoma brucei |
NMT | - |
Homo sapiens |
NMT | - |
Leishmania donovani |
NMT | - |
Plasmodium falciparum |
NMT | - |
Trypanosoma brucei |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.4 | - |
assay at | Homo sapiens |
7.4 | - |
assay at | Leishmania donovani |
7.4 | - |
assay at | Plasmodium falciparum |
7.4 | - |
assay at | Trypanosoma brucei |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
additional information | - |
IC50 values of different inhibitors, overview | Homo sapiens | additional information | |
additional information | - |
IC50 values of different inhibitors, overview | Leishmania donovani | additional information | |
additional information | - |
IC50 values of different inhibitors, overview | Plasmodium falciparum | additional information | |
additional information | - |
IC50 values of different inhibitors, overview | Trypanosoma brucei | additional information |